ESC TV at #ACC22 - Expert Insights on VALOR-HCM and MAVA-LTE Study

(1:59)

AHA 24: VALOR-HCM: Mavacamten in Patients with Obstructive HCM Referred for Septal Reduction Therapy

(10:32)

ACC 22: Findings from the VALOR-HCM Trial | Dr Milind Y Desai

(9:39)

Discussing the VALOR-HCM Trial

(11:16)

Drug Reduces the Need for Surgery in Nearly 90% of Patients with HCM, Cleveland Clinic Study Shows

(1:52)

VALOR-HCM: Mavacamten in Obstructive Hypertrophic Cardiomyopathy

(15:42)

After Shocks with Dr. Milind Desai on the VALOR-HCM trial

(19:9)

VALOR-HCM Shows Promise for Patients With Hypertrophic Cardiomyopathy (for Healthcare Professionals)

(9:56)

ACC CVRI: Journal Club: VALOR-HCM Trial - By Tess Calcagno

(31:48)

Cardiac Myosin Inhibitors and HCM: Therapy of the (Near) Future

(56:23)

Clinical Trial Shows Drug is Effective in Nearly 80% of Patients with Hypertrophic Cardiomyopathy

(2:10)

Pushing Back Against HCM: The Role of Cardiac Myosin Inhibitors

(1:1:14)

Removing Obstructions for Improved HCM Care: Leveling Up Diagnosis and Management

(50:1econd)

EXPLORER-HCM trial results - Daniel Jacoby, MD

(8:19)

Mavacamten for HCM

(16:29)

New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy

(29:30)

ACC Cardiology Hour With Dr. Valentin Fuster | ACC.22 Day 1

(37:9)

New Treatment Option for Hypertrophic Cardiomyopathy | Mavacamten

(5:37)

ACC 22: MAVA-LTE Shows Improvement in NYHA Class in Patients Treated with Mavacamten | Dr Rader

(7:20)